BioLargo, Inc. · OTC:BLGO

BioLargo — Q2 2025 Earnings Presentation

15 slides from BioLargo's earnings presentation, Aug 15, 2025

  1. Slide 1: We Make Life Better

    We Make Life Better S BioLargo The innovation engine for a better tomorrow Q2 2025 Earnings Call Stock Symbol: Presentation OTCQX:BLGO

  2. Slide 2: Safe Harbor Statement

    Safe Harbor Statement All statements, other than statements of historical fact, included in this presentation and management's explanation and discussion of this presentation, regarding our strategy, future operations, future financial position, future revenues, projected costs, prospects and plans

  3. Slide 3: Who we are

    Who we are > Innovators, > Passionate about > Driven by a mission scientists, engineers, sustainability and to make life better and entrepreneurs human health

  4. Slide 4: What we do

    What we do > Best-in-class > Focus on problems > Aim for solutions for without good partnerships and cleantech problems solutions spin-outs to capitalize on our IP argo 4

  5. Slide 5: The BioLargo Innovation Engine

    The BioLargo Innovation Engine (y BioLargo We Make Life Better Investing in... 6 BioLargo Se Canada® 1 1 BioLargo . ENERGY |@ civRa TECHNOLOGIES Medical Technologies Inc __ ef = Gnwavecnenta. || = BioLargo ~ WSF ‘SSS courreanr « sovurrons » recnwouocres (Biolargo 5

  6. Slide 6: The Unseen Value of the BioLargo Portfolio

    11 Biolargo The Unseen Value of the BioLargo Portfolio ENERGY TECHNOLOGIES * Unmatched technologies z * Capital-conserving strategy —— * Highly qualified people ' ° =. BioLargo * Driven for high impact These are targeted minimum future values for our portfolio companies, based on management's modeli

  7. Slide 7: Net Stockholder's Equity

    MILLIONS NET STOCKHOLDER'S EQUITY 2018 2019 0 2021 2022 2023 2024 $@) ai $@) Trends are not necessarily indicative of future performance $6.06 M Q2 OF 2025

  8. Slide 8: Annual Run Rate and Q2 2025 Financials

    MILLIONS $20 $18 $16 $14 $12 $10 $8 $6 $4 $2 $0 ANNUAL RUN RATE 2018 2019 2020 2021 2022 2023 2024 2025 RUN RATE AS OF Q2 *Trends are not necessarily indicative of future performance, and future revenues are highly dependent on our partners’ performance. Q2 2025 Financials: Revenue * $2.78 million v

  9. Slide 9: The BioLargo Family of Companies

    ioLargo We Make Life Better The BioLargo b Family of Companies BioLargo, Inc. is a sustainable science, technology & full-service enviromental BioLargo § auiéusmera i h kes life liverit Id-cl engineering company that makeslife better by delivering world-class Nviewnones products and services across

  10. Slide 10: Summary of Highlights for Subsidiaries

    (p Biokargo | Arvendi Summary of Highlights for Subsidiaries 6 BioLargo 10

  11. Slide 11: Clyra Medical Technologies: Entering the Next Stage of Commercialization

    Clyra Medical Technologies CLYRA’ Medical Technologies Inc Entering the Next Stage of Commercialization Expanded Market Access — Sales & distribution agreements covering U.S. & international markets; expected to make products available to 6,100 hospitals, 6,300 surgery centers, and 2,200 wound care

  12. Slide 12: Cellinity Battery Technology: Transforming Energy Storage

    Cellinity Battery Technology BioLargo ENERGY TECHNOLOGIES Transforming Energy Storage Proven Performance — Built & tested prototypes confirming: * High energy density & voltage * Long cycle life & capacity retention * Safety (no runaway fire risk, even under damage) Third-Party Validation — U.S. BES

  13. Slide 13: PFAS Treatment and Other Water Treatment Technologies

    PFAS Treatment and Other Water Treatment Technologies >. BioLargo > courenenr « souurzons « TecnoLocTES, From Pilot to Commercial Rollout First paid PFAS treatment project (New Jersey) — AEC unit delivered. Performance breakthroughs * Removed PFAS <4 ppt (exceeds new EPA advisory) * Reduced salts/io

  14. Slide 14: ONM Environmental and Private Label Products

    ONM Environmental and Private Label Products _ fo CAVENIRONYENTAL a * Pooph Brand — Situation & Path Forward + Situation + Revenue decline since Q2 2024 peak * Slower payments from key customer, increased receivables, decreased in cash * Stock price pressure from limited equity line use * Action + N

  15. Slide 15: Engineering & Environmental Services

    Revenue up — strong demand for environmental engineering services. Engineering & Key Growth Drivers « Multi-base U.S. Air Force air quality contracts. Environmental * Expansion into industrial wastewater treatment & odor Services control (food processing/manufacturing — SE U.S.). * Growth in regulat

BioLargo — Q2 2025 Earnings Presentation on 6ix